GlassScriptPhysician profile
Bob D Kurts
NPI 1033144712
$3,942.56
in general payments reported to CMS, 2019-2025
26 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $603 · 2024: $1,330 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,079.32 | 2023-2025 | |
| Pfizer INC. | $408.97 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $331.16 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Daiichi Sankyo INC. | $261.16 | 2024-2025 | Injectafer |
| Novo Nordisk INC | $259.13 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $241.95 | 2024-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $201.09 | 2024-2025 | Jardiance, Zepbound, Kisunla |
| Dexcom, INC. | $150.66 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $139.20 | 2023 | Venaseal |
| Edwards Lifesciences Corporation | $136.19 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $130.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.74 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $80.40 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $54.37 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $53.55 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $48.66 | 2025 | Zenpep |
| Astellas Pharma US INC | $44.45 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.30 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $34.76 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $27.29 | 2025 | |
| Optinose US, INC. | $23.48 | 2024 | |
| Viatris Specialty LLC | $23.42 | 2025 | Yupelri |
| Verity Pharmaceuticals INC. | $22.62 | 2025 | Tlando |
| Tandem Diabetes Care, INC. | $14.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi Pasteur INC. | $13.99 | 2024 | |
| Merck Sharp & Dohme LLC | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Kurts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.